Drug Trial Radar · NCT04115306
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Planned (sponsor's estimate)
Start
Nov 14, 2019
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Phoenix Molecular DesignsIndustry
- Sponsor type
- Industry
- First posted
- Oct 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Conditions
- Metastatic Breast Cancer
Interventions
PMD-026Drug
Investigational Drug
fulvestrantDrug
SERDs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of PMD-026 in combination with fulvestrant in patients with HR+/HER2- previously treated breast cancerTime frame: 6 weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
City of Hope
Duarte, California
City of Hope Orange County, Lennar
Irvine, California
University of California, Los Angeles (UCLA)
Los Angeles, California
Moffitt Cancer Center
Tampa, Florida
City of Hope Chicago
Zion, Illinois
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Profound Research
Farmington Hills, Michigan
Ohio State University
Columbus, Ohio
South Texas Accelerated Research Therapeutics
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.